Antibiotic Sponsors Get More Flexibility In Final Antibiotic Guidance
Executive Summary
FDA is less prescriptive on a variety of clinical development options, including inclusion and exclusion criteria, dosing, study comparators and safety in final document on antibiotics for complicated intra-abdominal infection.